ALNY FY 2016 Earnings — Alnylam Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

ALNYAlnylam Pharmaceuticals, Inc.

$42B

FY 2016 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$47M+14.8% YoY

Gross Profit

$47M100.0% margin

Operating Income

-$425M-900.3% margin

Net Income

-$410M-869.6% margin

EPS (Diluted)

$-4.79

Cash Flow

Operating Cash Flow

-$308M

Free Cash Flow

-$372M

Stock-Based Comp.

$76M

Balance Sheet

Total Assets

$1.3B

Total Liabilities

$343M

Stockholders' Equity

$920M

Cash & Equivalents

$194M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$47M	$41M	+14.8%
Gross Profit	$47M	$41M	+14.8%
Operating Income	-$425M	-$296M	-43.4%
Net Income	-$410M	-$290M	-41.4%